This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Roederer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Roederer, M.

 Previous Article  |  Next Article 

Journal of Virology, May 2002, p. 4810-4821, Vol. 76, No. 10
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.10.4810-4821.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells

John R. Mascola,1* Mark K. Louder,1 Christine Winter,1 Ranjani Prabhakara,1 Stephen C. De Rosa,1 Daniel C. Douek,1 Brenna J. Hill,1 Dana Gabuzda,2 and Mario Roederer1

Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,1 Division of Human Retrovirology, Dana-Farber Cancer Institute, Boston, Massachusetts 021152

Received 4 December 2001/ Accepted 7 February 2002

There is currently intensive research on the design of novel human immunodeficiency virus type 1 (HIV-1) vaccine immunogens that can elicit potent neutralizing antibodies. A prerequisite for comparing and optimizing these strategies is the ability to precisely measure neutralizing antibody responses. To this end, we sought to develop an assay that directly quantifies single-round HIV-1 infection of peripheral blood mononuclear cells (PBMC). Initial experiments demonstrated that essentially all productively infected PBMC could be identified by flow cytometric detection of intracellular p24 antigen (p24-Ag). After infection of PBMC with HIV-1, p24+ lymphocytes could be distinguished beginning 1 day postinfection, and the majority of CD8- T cells were p24-Ag positive by 3 to 4 days postinfection. To directly quantify first-round infection, we included a protease inhibitor in PBMC cultures. The resulting 2-day assay was highly sensitive and specific for the detection of HIV-1-infected PBMC. Serial dilutions of virus stocks demonstrated that the number of target cells infected was directly related to the amount of infectious virus input into the assay. In neutralization assays, the flow cytometric enumeration of first-round infection of PBMC provided quantitative data on the number of target cells infected and on the inactivation of infectious virus due to reaction with antibody. We also used this single-round assay to compare the percentage of cells expressing p24-Ag to the number of copies of HIV-1 gag per 100 PBMC. The precision and reproducibility of this assay will facilitate the measurement of HIV-1 neutralization, particularly incrementally improved neutralizing antibody responses generated by new candidate vaccines.


* Corresponding author. Mailing address: Vaccine Research Center, NIAID, NIH, 40 Convent Dr., Bethesda, MD 20892. Phone: (301) 594-8487. Fax: (301) 480-2788. E-mail: jmascola{at}nih.gov.


Journal of Virology, May 2002, p. 4810-4821, Vol. 76, No. 10
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.10.4810-4821.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Ogert, R. A., Ba, L., Hou, Y., Buontempo, C., Qiu, P., Duca, J., Murgolo, N., Buontempo, P., Ralston, R., Howe, J. A. (2009). Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc. J. Virol. 83: 12151-12163 [Abstract] [Full Text]  
  • Li, Y., Svehla, K., Louder, M. K., Wycuff, D., Phogat, S., Tang, M., Migueles, S. A., Wu, X., Phogat, A., Shaw, G. M., Connors, M., Hoxie, J., Mascola, J. R., Wyatt, R. (2009). Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. J. Virol. 83: 1045-1059 [Abstract] [Full Text]  
  • Dey, B., Pancera, M., Svehla, K., Shu, Y., Xiang, S.-H., Vainshtein, J., Li, Y., Sodroski, J., Kwong, P. D., Mascola, J. R., Wyatt, R. (2007). Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity. J. Virol. 81: 5579-5593 [Abstract] [Full Text]  
  • Kim, J.-O., Chakrabarti, B. K., Guha-Niyogi, A., Louder, M. K., Mascola, J. R., Ganesh, L., Nabel, G. J. (2007). Lysis of Human Immunodeficiency Virus Type 1 by a Specific Secreted Human Phospholipase A2. J. Virol. 81: 1444-1450 [Abstract] [Full Text]  
  • Bolesta, E., Kowalczyk, A., Wierzbicki, A., Eppolito, C., Kaneko, Y., Takiguchi, M., Stamatatos, L., Shrikant, P. A., Kozbor, D. (2006). Increased Level and Longevity of Protective Immune Responses Induced by DNA Vaccine Expressing the HIV-1 Env Glycoprotein when Combined with IL-21 and IL-15 Gene Delivery. J. Immunol. 177: 177-191 [Abstract] [Full Text]  
  • Holl, V., Peressin, M., Schmidt, S., Decoville, T., Zolla-Pazner, S., Aubertin, A.-M., Moog, C. (2006). Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107: 4466-4474 [Abstract] [Full Text]  
  • Li, Y., Svehla, K., Mathy, N. L., Voss, G., Mascola, J. R., Wyatt, R. (2006). Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants. J. Virol. 80: 1414-1426 [Abstract] [Full Text]  
  • Forsell, M. N. E., Li, Y., Sundback, M., Svehla, K., Liljestrom, P., Mascola, J. R., Wyatt, R., Hedestam, G. B. K. (2005). Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. J. Virol. 79: 10902-10914 [Abstract] [Full Text]  
  • Mascola, J. R., D'Souza, P., Gilbert, P., Hahn, B. H., Haigwood, N. L., Morris, L., Petropoulos, C. J., Polonis, V. R., Sarzotti, M., Montefiori, D. C. (2005). Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines. J. Virol. 79: 10103-10107 [Full Text]  
  • Brown, B. K., Darden, J. M., Tovanabutra, S., Oblander, T., Frost, J., Sanders-Buell, E., de Souza, M. S., Birx, D. L., McCutchan, F. E., Polonis, V. R. (2005). Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines. J. Virol. 79: 6089-6101 [Abstract] [Full Text]  
  • Seaman, M. S., Xu, L., Beaudry, K., Martin, K. L., Beddall, M. H., Miura, A., Sambor, A., Chakrabarti, B. K., Huang, Y., Bailer, R., Koup, R. A., Mascola, J. R., Nabel, G. J., Letvin, N. L. (2005). Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys. J. Virol. 79: 2956-2963 [Abstract] [Full Text]  
  • Kalia, V., Sarkar, S., Gupta, P., Montelaro, R. C. (2005). Antibody Neutralization Escape Mediated by Point Mutations in the Intracytoplasmic Tail of Human Immunodeficiency Virus Type 1 gp41. J. Virol. 79: 2097-2107 [Abstract] [Full Text]  
  • Mascola, J. R., Sambor, A., Beaudry, K., Santra, S., Welcher, B., Louder, M. K., VanCott, T. C., Huang, Y., Chakrabarti, B. K., Kong, W.-P., Yang, Z.-Y., Xu, L., Montefiori, D. C., Nabel, G. J., Letvin, N. L. (2005). Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins. J. Virol. 79: 771-779 [Abstract] [Full Text]  
  • Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., Petropoulos, C. J., Burton, D. R. (2004). Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. J. Virol. 78: 13232-13252 [Abstract] [Full Text]  
  • Holl, V., Hemmerter, S., Burrer, R., Schmidt, S., Bohbot, A., Aubertin, A.-M., Moog, C. (2004). Involvement of Fc{gamma}R I (CD64) in the Mechanism of HIV-1 Inhibition by Polyclonal IgG Purified from Infected Patients in Cultured Monocyte-Derived Macrophages. J. Immunol. 173: 6274-6283 [Abstract] [Full Text]  
  • Ganesh, L., Leung, K., Lore, K., Levin, R., Panet, A., Schwartz, O., Koup, R. A., Nabel, G. J. (2004). Infection of Specific Dendritic Cells by CCR5-Tropic Human Immunodeficiency Virus Type 1 Promotes Cell-Mediated Transmission of Virus Resistant to Broadly Neutralizing Antibodies. J. Virol. 78: 11980-11987 [Abstract] [Full Text]  
  • Ofek, G., Tang, M., Sambor, A., Katinger, H., Mascola, J. R., Wyatt, R., Kwong, P. D. (2004). Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope. J. Virol. 78: 10724-10737 [Abstract] [Full Text]  
  • Iordanskiy, S., Zhao, Y., Dubrovsky, L., Iordanskaya, T., Chen, M., Liang, D., Bukrinsky, M. (2004). Heat Shock Protein 70 Protects Cells from Cell Cycle Arrest and Apoptosis Induced by Human Immunodeficiency Virus Type 1 Viral Protein R. J. Virol. 78: 9697-9704 [Abstract] [Full Text]  
  • Liao, H.-X., Alam, S. M., Mascola, J. R., Robinson, J., Ma, B., Montefiori, D. C., Rhein, M., Sutherland, L. L., Scearce, R., Haynes, B. F. (2004). Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins. J. Virol. 78: 5270-5278 [Abstract] [Full Text]  
  • Yang, Z.-y., Chakrabarti, B. K., Xu, L., Welcher, B., Kong, W.-p., Leung, K., Panet, A., Mascola, J. R., Nabel, G. J. (2004). Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope. J. Virol. 78: 4029-4036 [Abstract] [Full Text]  
  • Gorny, M. K., Revesz, K., Williams, C., Volsky, B., Louder, M. K., Anyangwe, C. A., Krachmarov, C., Kayman, S. C., Pinter, A., Nadas, A., Nyambi, P. N., Mascola, J. R., Zolla-Pazner, S. (2004). The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. J. Virol. 78: 2394-2404 [Abstract] [Full Text]  
  • Mascola, J. R., Lewis, M. G., VanCott, T. C., Stiegler, G., Katinger, H., Seaman, M., Beaudry, K., Barouch, D. H., Korioth-Schmitz, B., Krivulka, G., Sambor, A., Welcher, B., Douek, D. C., Montefiori, D. C., Shiver, J. W., Poignard, P., Burton, D. R., Letvin, N. L. (2003). Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies. J. Virol. 77: 10348-10356 [Abstract] [Full Text]